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Background: Viral resistance to antiretroviral therapy threatens our best methods to control and prevent HIV
infection. Current drug resistance genotyping methods are costly, optimized for subtype B virus, and primarily
detect resistance mutations to protease and reverse transcriptase inhibitors. With the increasing use of integrase
inhibitors in first-line therapies, monitoring for integrase inhibitor drug resistance mutations is a priority. We
designed a universal primer pair to PCR amplify all major group M HIV-1 viruses for genotyping using Illumina
MiSeq to simultaneously detect drug resistance mutations associated with protease, nucleoside reverse transcriptase,
non-nucleoside reverse transcriptase, and integrase inhibitors.
Results: A universal primer pair targeting the HIV pol gene was used to successfully PCR amplify HIV isolates
representing subtypes A, B, C, D, CRF01_AE and CRF02_AG. The universal primers were then tested on 62 samples from
a US cohort of injection drug users failing treatment after release from prison. 94% of the samples were successfully
genotyped for known drug resistance mutations in the protease, reverse transcriptase and integrase gene products.
Control experiments demonstrate that mutations present at≥ 2% frequency are reliably detected and above the
threshold of error for this method. New drug resistance mutations not found in the baseline sample were identified in
54% of the patient samples after treatment failure. 86% of patients with major drug resistance mutations had 1 or
more mutations associated with drug resistance to the treatment regimen at the time point of treatment failure. 59%
of the emerging mutations were found at frequencies between 2% and 20% of the total sequences generated, below
the estimated limit of detection of current FDA-approved genotyping techniques. Primary plasma samples with viral
loads as low as 799 copies/ml were successfully genotyped using this method.
Conclusions: Here we present an Illumina MiSeq-based HIV drug resistance genotyping assay. Our data suggests that
this universal assay works across all major group M HIV-1 subtypes and identifies all drug resistance mutations in the
pol gene known to confer resistance to protease, reverse transcriptase and integrase inhibitors. This high-throughput
and sensitive assay could significantly improve access to drug resistance genotyping worldwide.
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Antiretroviral therapy has been shown to be the most
potent intervention for both treating and preventing
HIV [1,2]. However, the effectiveness of antiretroviral
drugs is threatened by the development and transmission
of drug resistant virus [3,4]. HIV drug resistance genotyping
is a clinically important tool to detect the emergence of
viral resistance and maximize the benefit of current
treatment options [5,6]. New sequencing techniques
can improve sensitivity of drug resistance genotyping
while also reducing costs. We recently published a paper
outlining the benefits of using Roche/454 pyrosequencing
to detect HIV drug resistance mutations with a capacity to
reduce costs by 5-fold [7]. As sequencing technologies
have continually improved, the genotyping methods used
in clinical settings to detect drug resistance have failed to
evolve at a comparable pace. Here we present an updated
deep sequencing genotyping assay utilizing the Illumina
MiSeq. Advantages of this novel method over our
Roche/454 approach include fewer systemic basecalling
sequencing errors, increased multiplexing, use of a
FDA-approved sequencing platform, detection of drug
resistance to integrase inhibitors in addition to reverse
transcription inhibitors and protease inhibitors with a
single amplicon, and finally, simultaneous genotyping
of all major group M HIV subtypes with a single set
of amplification primers.
Detection of Integrase inhibitor drug resistance is
particularly noteable because integrase inhibitors are
now recommended by the department of Health and
Human Services as part of first-line antiretroviral
therapy in the United States [8]. The use of integrase
inhibitors as part of initial antiretroviral therapy is expected
to increase because of the recent FDA approval of a new
once daily integrase inhibitor (elvitegravir) that can be
co-formulated with emtricitabine, tenofovir disoproxyl
fumarate and cobicistat as a single pill once daily
regimen (STRIBILD) [9]. Current genotyping methods
used to detect drug resistance to integrase inhibitors
are limited and typically involve a separate assay from that
used to identify drug resistance to reverse transcriptase
and protease inhibitors [10,11]. However, due to proximity
of the integrase protein-coding region to the reverse
transcriptase and protease protein-coding region in
the viral genome, it is feasible to incorporate drug resistance
genotyping of all three gene products together from a single
PCR amplicon. By using a single amplicon, no additional
labor or expense is added to the assay already detecting pro-
tease and reverse transcriptase drug resistance mutations.
The FDA-approved HIV drug resistance genotyping
assays currently in use were developed using HIV group M
subtype B viruses [12]. However, subtype C comprises about
half of the worldwide epidemic followed by subtype A (12%)
and then B (11%) [13]. Current commercial genotypingassays perform rather poorly with non-subtype B viruses
because seven sets of sequencing primers must bind to
highly variable targets during sequencing [12,14].
Therefore, non-B assays require more replication and for
many samples, fail altogether with the current commer-
cially available genotyping assays. There have been many
successful adaptations of the commercial Sanger-based
genotyping assay to improve genotyping of non-B HIV
subtypes, however, these assays do not include detection of
integrase inhibitor mutations and are less sensitive than
next-generation sequencing approaches [15-21].
Cost is a major barrier to drug resistance genotyping in
resource-limited settings. Deep sequencing technologies
have significantly reduced the cost of sequencing but are
not yet incorporated into standard HIV drug resistance
genotyping. An Illumina MiSeq sequencer can yield over
25 million sequencing reads per run with the latest tech-
nology (MiSeq reagent kit v3). Through multiplexing, 96
samples can be processed in one run, bringing the cost of
sequencing alone to < $10/sample. This is 3-fold less than
Sanger-based sequencing. In addition, the clonal nature of
deep sequencing methods along with the large number of
sequencing reads generated improves sensitivity for the de-
tection of mutations compared to Sanger-based sequencing
[12,22,23]. Lastly, the Illumina MiSeq platform is currently
the least error-prone deep sequencing method [24,25].
Results and discussion
PCR primers amplify major group M HIV subtypes A, B, C,
D, CRF01_AE and CRF02_AG
HIV sequences from all subtypes found in the Los Alamos
National Labs HIV database (http://www.hiv.lanl.gov)
were used to design a universal primer set to amplify all
major HIV subtypes as described in the Methods section
(HIV2252-F and HIV5073-R). We obtained HIV isolates
from the International Panel of 60 HIV-1 isolates from the
NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH (cat. #11412) representing
subtypes A, B, C, D, CRF01_AE and CRF02_AG. We
selected 19 isolates to represent geographically diverse
regions as shown in Table 1, isolated viral RNA and
performed one step RT-PCR to create PCR amplicons
according to the protocol outlined in the Methods section.
Despite a wide range of TCID50 and/or P24 content in the
panel isolates tested, all isolates yielded a strong amplifica-
tion product after 40 cycles of PCR as visualized on a 1%
agarose gel (Additional file 1). These results suggest that
the primer pair designed for this method could be used to
amplify all major group M HIV subtypes.
Error associated with the genotyping assay
To assess the error associated with the RT-PCR amplifica-
tion and sequencing of samples, a clonal virus stock
was generated from a plasmid containing the HXB2
Table 1 HIV-1 subtypes tested with the universal primer set
Virus Subtype TCID/mL* P24 ng/mL* RT-PCR
92UG_029 A 1.26x105 150 +
93RW_024 A NA NA +
00KE-KER2008 A 102.60 57 +
84US_MNp B 1.02x104 634 +
85US_BA-L B 5.62x106 39.3 +
91US_1 B 105.0 294 +
94US_33931N B 103.10 235 +
00TZ_A246 C 1.45x104 NA +
02ET_14 C 104.10 12.2 +
94IN_20635-4 C NA NA +
90SE_364 C 106.0 157 +
98US_MSC5016 C 103.85 11.5 +
93UG_065 D NA NA +
98UG_57128 D 102.39 13 +
99UG_A03349M1 D 2.05x104 290 +
90TH_CM244 CRF01_AE 4.1x104 88 +
97TH_NP1525 CRF01_AE 7.11x103 90 +
91DJ_263 CRF02_AG 2.3x104 NA +
98US_MSC5007 CRF02_AG 4x104 127 +
* Provided by the NIH AIDS Research and Reference Reagent Program.
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stock as described in the Methods section and as
depicted in Figure 1. We assessed all nucleotide variants
present above a 0.1% frequency across the entire Pol
region sequenced from two independent amplifications
and sequencing runs of the HXB2 clonal stock amplicons.
Any variant found in our clonal virus stock is expected to
be due to PCR or sequencing errors. The frequency of
these variants determined our error limit threshold for
this assay. Nucleotide polymorphisms that result in a
non-synonymous amino acid changes are presented in
Additional file 2. Most nucleotide variants were
present at frequencies less than 0.4%, however, two
regions contained variants at frequencies between 0.6% and
0.9%. One insertion was present at a frequency of 0.9% that
was associated with the end of the first of two back-to-back
long homopolymer runs (AAAAAAGAAAAAA) found
near the K101 and K103 drug resistance mutations, but not
within them. Another single nucleotide polymorphism
was found at a 0.6-0.7% frequency downstream of the
integrase drug resistance mutations (nucleotide position
2779 (R275R in integrase)). This polymorphism was a
synonymous change that did not alter the amino acid
sequence. These results suggest that we see some evidence
of increased mutations associated with homopolymers in
Illumina data, as has been published, but that those
mutations are not present above a 1% frequency nor
do they impact the codons directly associated withdrug resistance [26]. In addition, errors associated with
the GGC sequence motif were also not found above a
frequency of 0.5%. We also detected five variants present
at 99.9-100% frequencies that are likely differences
between the modified HXB2 plasmid we sequenced and
the published HXB2 strain and were ignored as variants
caused by PCR or sequencing errors (non-synonymous
changes shown in Additional file 2). Overall, no vari-
ants were found above a 0.9% frequency in our clonal
HIV stock.
When specifically assessing nucleotide variants associated
with amino acid changes linked to HIV drug resistance
across the pol gene, we found that all variants within
drug resistance sites were present at frequencies
below 0.3% of the viruses sampled from our clonal
stock (Additional file 2). Therefore, given both the
error limits within the drug resistance sites and outside of
the drug resistance sites, variants found at frequencies
greater than 1%, are likely authentic, while those below
this threshold may result from RT-PCR and sequencing
artifacts. Repeated sequencing of a subset of samples
revealed that variants above 2.0% are consistently detected,
while some variants found at frequencies between 1.0% and
2.0% are not (Additional file 2). Therefore, we designated
2.0% as the minimum threshold frequency for variants in
subsequent experiments. Previous studies suggest that
incorrect nucleotide incorporation associated with PCR
error typically occurs at rates under 2.0%, supporting
our finding that variants found at a greater than 2.0%
frequency are likely true variants [27]. Also, the error
rates described here are very specific to the precise
protocol, polymerases and sequencing kit used in this
manuscript. Error rates should be reassessed if any
changes to the method are made.
To determine whether nested PCR increased the error
associated with low-frequency mutations, we performed
the same test as described above, but subjected the
clonal virus stock to two rounds of PCR under the same
conditions used for primary samples. Once again, variants
from the expected HXB2 sequence were present below a
frequency of 1.0% (Additional file 2).
We previously published a high throughput next-
generation-based HIV drug resistance genotyping
technique based on the Roche/454 sequencing platform
[7]. One of the disadvantages of this system was the error
associated with nucleotide homopolymer runs resulting
from the sequencing chemistry used in the Roche/454
system. Sequence regions with homopolymer runs of
three or more nucleotides are often miscalled, presenting
a problem for some important drug resistance mutations
like K103N and K65R that are encoded by homopolymeric
nucleotide sequences. The competitive addition of revers-
ible terminators used in Illumina’s sequencing technology
greatly reduces homopolymer errors resulting in more
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Figure 1 Preparation and sequencing of samples. (A) Plasma is isolated from whole blood from up to 96 samples. (B) Viral RNA is isolated
from up to 1 ml of plasma. (C) Viral RNA is used in a one-step RT-PCR amplification of a 2.8 kb region of the pol gene. When nested PCR is
required, a 4.8 kb region is amplified as an external PCR followed by the 2.8 kb nested PCR of the pol gene. (D) PCR products are purified either
by gel electrophoresis followed by gel extraction or through size-exclusion magnetic beads and then quantitated using the Qubit system.
(E) Purified products are randomly fragmented and subjected to a limited cycle PCR to add sequencing adaptors and indices used for multiplexing
samples. (F) Newly created libraries are purified by size-exclusion magnetic beads to remove short fragments. (G) The average size of the library
fragments are calculated by bioanalysis and final concentration of the libraries calculated by Qubit are used to normalize each library and pool multiple
libraries together at equimolar ratios. (H) Libraries are sequenced on the Illumina MiSeq. (I) Geneious Pro Software is used to trim sequencing reads
based on quality scores and assemble the reads to a HXB2 reference sequence annotated with HIV drug resistance mutations. Geneious is used to
identify variants within each sample relative to HXB2. Finally, variants associated with drug resistance mutations were extracted and their frequencies
noted. Details about the analysis parameters are outlined in the Methods section.
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these important sites. After trimming, the nucleotides
representing the homopolymers in K103N and K65R
mutations found in our patient samples maintained
Phred quality scores >Q30 (or p = 0.001), lending greater
confidence to the nucleotide bases called in these regions
than was afforded by the Roche/454 assay where quality
scores in these regions often dropped below Q20.
PCR amplification using specimens from ALIVE
We obtained plasma samples collected from adults with a
history of injection drug use who participated in the AIDS
Linked to the IntraVenous Experience (ALIVE) study inBaltimore, MD [28]. Previous research with this cohort
showed that virologic failure occurs with high frequency
when participants experience incarceration, but it is not
known whether the viral rebound that occurs in this
setting is associated with development of drug resistance
[29]. To answer this question while testing our
method on primary HIV isolates, we genotyped HIV
RNA from stored plasma specimens obtained from
ALIVE participants. First, we isolated plasma viral
RNA from 29 patients with samples from at least two time
points for a total of 62 samples (see Additional file 3). 94%
(58/62) of the samples were successfully amplified and
sequenced, though 9 of these samples required nested
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or required nested PCR either had low viral load values
(<1,000 copies/ml) or were 5–13 years old and underwent
multiple freeze-thaw cycles prior to PCR amplification
(see Additional file 3). Of the samples that were success-
fully sequenced with viral loads above 2,000 copies/ml,
94% (48/51) of the samples amplified with one round of
PCR using the universal primer set. Since each unique
patient sample amplified in at least one time point
and our primers are universal for multiple subtypes,
we do not believe that the subtype of the patient
virus was the reason for the failure to amplify in
three samples. In any event, our sequences clustered
with subtype B virus in phylogenetic analysis of the pol
gene sequences (Additional file 4). Overall, we expect that
if this method was used on recently collected samples with
viral loads greater than 2,000 copies/ml for timely
genotyping assays, nested PCR would not be required.
Lastly, we were able to sequence primary isolate samples
with a viral load as low as 799 copies/ml with nested
PCR and 1070 copies/ml with a single round of PCR
(see Additional file 3). However, each patient sample
likely exhibits a unique limit of detection depending
on the sequence concordance between the primers
and patient virus.
Sequencing using specimens from ALIVE
Including controls, 63 PCR amplicons were fragmented
and pooled together in a single MiSeq run. The cluster
density of the sequencing run was 663 k/mm2 and the
average number of sequence reads obtained per sample
was 146,780 (range: 74,848-244,428, stdev: 34,556). The
coverage, or number of sequences that represent each
drug resistance site after mapping to a reference sequence,
varied between each patient and across the pol gene.




































Figure 2 Representative sequence coverage across the pol gene.
The number of sequences representing each nucleotide across the pol
gene (i.e. “coverage”) is shown for all sites that differed from HXB2 in a
representative sample (sample 16 v11). Sites of all known drug
resistance mutations are over-layed as red squares and the graph is
divided into sections representing mutations associated with protease,
reverse transcriptase or integrase drug resistance for reference.(patient 16) with 142,169 total reads. All nucleotides
present between the first protease inhibitor resistance
mutation (HXB2 position 1826) and last integrase inhibitor
drug resistance mutation (HXB2 position 4238) were
represented by more than 1,000 sequence reads in
this patient (red squares in Figure 2). The goal of this
method to generate a depth of coverage of >1000
sequencing reads/nucleotide position and in fact, at the
major drug resistance sites, the average coverage of each
mutation was over 1000 sequence reads (Table 2).
Based on previous next-generation sequencing work,
to accurately detect mutations at a frequency of 1.0%,
minimal coverage requirements have ranged from 300
to 1850 sequencing reads [22,30-32]. With our minimum
frequency threshold set to 2.0%, requiring a minimum of
1000 sequencing reads is conservative relative to previous
publications. Across all samples, the average number of
sequences representing each drug resistance site was
3,795 sequences. While coverage varied across the pol
gene, the quality of all assembled sequences was very high
due to the stringent trimming parameters (see Methods
section) used during analysis.to remove nucleotides whose
base call was deemed less than 99.9% accurate by the
sequencing software prior to assembly (phred quality
score > Q30 or p > 0.001). Note that this data was
generated prior to the release of the latest MiSeq sequen-
cing kits, which now have an average output capacity of
25 million reads per sequencing run. This would more
than double the reads obtained per sample as well as
double the sequence read coverage at each nucleotide site
given the same pooling strategy.
In general, across all patient samples and as exemplified
in Figure 2, the coverage of the nucleotides associated with
the protease inhibitor mutations found closest to the 5′
end of protease were lower than the number of sequences
representing all other drug resistance mutation sites
downstream. There are four accessory mutations (L10,
V11, G16E and K20) and zero major mutations that
sit close to the end of the original pol gene PCR
amplicon that are sometimes affected by this reduced
coverage (Table 2). These four sites are less represented
because transposon-based fragmentation creates fewer
fragments at the ends of the input DNA strand (original
full-length pol gene amplicon) that have the necessary
adaptor required for sequencing. Instead of 1000s of reads,
sometimes these mutations are represented by hundreds
of reads in this cohort (see Table 2). For the two mutations
(L10 and V11) in our cohort that are represented by an
average of 300 sequencing reads, a minimum frequency
requirement could be increased to 6.5% to ensure that at
least 20 reads are found containing the mutation, keeping
the requirement the same as a mutation found at a
2% frequency in 1000 sequencing reads. This caveat to this
approach could be solved by generating a primer that sits
Table 2 Average sequencing read coverage for all drug
resistance mutations identified in the ALIVE cohort










































*Boldface mutations are major drug resistance mutations, non-boldface
mutations are accessory mutations.
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design is constrained when trying to keep the primers
universal across multiple HIV clades. As mentioned above,with the latest MiSeq sequencing kits, coverage will also
double at these sites. Lastly, reducing the multiplexing
would also yield greater coverage per sample at this site if
coverage of these mutations was a concern. The data from
this patient cohort shows that this method combining 63
samples together results in characterization of major drug
resistance mutations with thousands of sequencing
reads representing most mutations. Based on our average
coverage of 3,795 sequences, extrapolation would suggest
that 96 samples could be pooled together and average
coverage of major drug resistance mutations would still be
over 1,000 sequences per drug resistance site when optimal
cluster density is reached on the MiSeq sequencing chip.
This would further increase by at least 2-fold by using the
latest MiSeq reagent kit V3 technology.
Although transposon-based fragmentation is theoretically
unbiased, we observed consistently greater coverage in the
reverse transcriptase protein coding region than protease
and integrase coding regions across all samples, as exempli-
fied in Figure 2. This similar coverage pattern between
different samples over the same genetic regions is similar to
that previously observed with whole genome HIV and
SIV sequencing using the same fragmentation method [33].
Therefore, it is likely that there is some bias in fragmenta-
tion that yields ideally sized fragments for sequencing in
some parts of the HIV genome over others.
Lastly, the assembled sequences were aligned and a
maximum likelihood phylogenetic analysis was performed
along with reference sequences from the panel of HIV
isolates that we PCR amplified with our universal primer
set (Additional file 4). As shown in Additional file 4, all
samples from this cohort cluster with subtype B viruses,
including the HXB2 control samples that we sequenced.
In addition, the two time points from each sample
clustered with each other and not with other samples,
indicating that there was no cross-contamination resulting
in the changes in drug resistance mutations found
between the two time points from each patient sample.
Drug resistance mutations detected in specimens from
ALIVE
To detect HIV drug resistance mutations in virus from
the 29 ALIVE participants failing treatment after release
from prison/jail, we analyzed the pol gene sequencing
reads from two time points. First, the ALIVE participants
successfully suppressed HIV before incarceration by using
antiretroviral therapy. The first time point we sampled
was at the time point just prior to this viral suppression.
Some patients were drug naïve at this time point, but
others were previously drug experienced (as outlined in
Additional file 3) and either changed regimens or began
taking ARTs after a break in treatment to reach viral
suppression at the subsequent time point. The second



























Figure 3 Characterization of the drug resistance mutations
identified in the ALIVE cohort after treatment failure. (A) The
frequency of different types of HIV drug resistance mutations found
in 26 patient samples with after treatment failure. Major mutations
are as defined by the Stanford drug resistance database and
accessory mutations are all other mutations associated with drug
resistance as designated by the International AIDS Society (IAS).
(B) Percentages of the 29 emerging mutations found at the second
time point but not first time for all participant samples that were
major or accessory mutations and whether the mutations rose
above the 20% threshold expected to be detected by commercial
HIV drug resistance genotyping techniques.
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jail or prison. We obtained sequence data from both time
points from 26/29 specimens. Relative to the first time
point sequenced (baseline), new drug resistance mutations
emerged in 54% (14/26) of the patients exhibiting treatment
failure that were not detected at baseline (Figure 3A and
Table 3). One additional sample (patient 27) contained
major drug resistance mutations at both time points tested
that may have contributed to treatment failure at the
second time point (Table 4). These mutations, I54V, L90M,
K103N and M184V, were present at frequencies >85% at
both time points with most being present at >99% of
sequences. The remaining samples without emerging
drug resistance mutations contained primarily accessory
mutations at baseline or at the second time point or very
low level major drug resistance mutations that disappeared
by the second time point and therefore likely do not
contribute to treatment failure. Therefore, these patients
may be failing treatment for reasons other than drug resist-
ance mutations in the pol gene product. For example, some
patients may fail due to lack of adherence or presence of
mutations in Gag or the cytoplasmic tail of Env, which
have been recently reported to affect drug resistance to
protease inhibitors [34-36]. In the future it will be possible
to expand our technique to include these regions outside
of the pol gene, however, it would require amplification
of more than one amplicon prior to fragmentation and
sequencing.
Association of major drug resistance mutations with
treatment in ALIVE
As a way to assess our drug resistance genotyping assay, we
compared the major drug resistance mutations identified
by our genotyping assay with the treatment regimens
reported by the ALIVE study participants at the time of
treatment failure. We define major drug resistance
mutations as those included in the Stanford Drug
Resistance Database matrices that are associated with
high levels of phenotypic drug resistance [37,38]. This
is opposed to accessory mutations whose role in
treatment failure is less clear. Overall, 57% (8/14) of
the patients with virus harboring any emerging drug
resistance mutations relative to the first time point
tested had major drug resistance mutations (Figure 3A and
Table 3). We focused our mutation/treatment association
analysis on these eight patients and analyzed the major
mutations found in their virus using the Stanford drug
resistance database Genotype Resistance Interpretation
calculator [37,38]. The results of the calculator were then
compared to each patient’s self-reported treatment regimen
at the time of failure (Table 4). Of the eight patients
harboring virus with major drug resistance mutations,
seven patients had virus with mutations associated with a
high level of drug resistance to one or more of the drugs
Table 3 Drug resistance mutations emerging after
incarceration in the ALIVE cohort
Drug class Mutation Sample #(s) (% frequency)













NRTI inhibitors M41L 2 (13.3%)
A62V 2 (3.1%)
M184V 2 (99.9%), 5 (82.8%), 9 (99.8%),
10 (100%), 16 (56.6%), 23 (68.5%)
NNRTI inhibitors K103N 5 (100%), 10 (100%), 23 (99.8%)
V108I 23 (59.8%)
E138KAGQR 16 (7.6%)
P225H 23 (55.3%), 10 (99.9%)
Integrase inhibitors S147G 16 (7.6%)
Boldface font = major mutation. Regular font = accessory mutation.
Dudley et al. Retrovirology  (  Page 8 of 15in their regimen at the time point of failure (boldface
in Table 4). Table 4 also shows the mutational load
(viral load*frequency of mutation) of each mutation
within each patient. M184V and K103N were the major
mutations associated with treatment failure in this cohort
and it is notable that the major drug resistance mutations
that correlate with the drug regimen at the point of
treatment failure are found at frequencies well above
50%, indicating drug selection pressure. As expected,
the major mutations identified in most of the patients
of this cohort using our genotyping technique associated
well with the treatment regimens reported by the patients
at the time of treatment failure.
Major drug resistance mutations emerging after treatment
failure were then compared with all drugs self-reported for
each individual during the course of all time points where
data was collected. As shown in figure 3B, almost half
(14/29) of all the 29 mutations emerging after treatment
failure were major mutations. Overall, 10/14 major drug
resistance mutations were associated with the patient
self-reported drug regimens from either the time
point of failure or previous time points (Table 4).
These mutations were found at frequencies >50%
while those that do not associate with the treatmentregimen are found at <20%. Altogether, these data are
consistent with the conclusion that this genotyping assay
is detecting drug resistance mutations that would be
expected based on the treatment regimens reported
by the participants in the ALIVE cohort.
Accessory drug resistance mutations detected in ALIVE
Accessory mutations are those that alone may not
render resistance, but may contribute to resistance
when combined with other mutations. All mutations
identified on the International AIDS Society (IAS) USA
drug resistance mutation list that were not part of the
Stanford drug resistance database major mutation matrices
were categorized as accessory mutations in this study. We
identified accessory mutations in 23% of ALIVE patient
samples that did not have major drug resistance mutations
at the time of treatment failure (Figure 3A). Most of these
mutations were present at frequencies <20% (Figure 3B
and Table 3). While it is likely that these accessory
mutations contributed to resistance, this cohort was
not appropriately powered to explore the correlations
between accessory mutations and drug resistance
more definitively.
Minority drug resistance variants in the ALIVE cohort
Currently, FDA-approved Sanger sequencing-based HIV
drug resistance genotyping methods such as ViroSeq
identify mutations present above a frequency of 20% within
a host’s viral population [12,22]. Therefore, mutations found
below this 20% frequency (i.e. minority variants) might be
missed by current commercial techniques. As shown
in figure 3B and detailed in Table 3, 59% (17/29) of all
drug resistance mutations found in the ALIVE cohort by
this genotyping technique were below the 20% frequency
limit of detection of current genotyping. This indicates
that the presented genotyping technique is likely more
sensitive than those currently available commercially.
Development of sensitive assays, like the genotyping
assay presented here, will support future studies designed
to delineate which minority mutations are important prior
to the start of specific antiretroviral therapy. In our cohort,
mutations likely contributing to treatment failure of a
given drug regimen were predominantly present at
frequencies >20%.
An important consideration when detecting lower
frequency mutations or variants from samples with
lower viral loads is reliability of the variant frequency
detected and possibility of template resampling. While
we were unable to do this with the presented cohort
due to sample limitations, PCR amplifying a sample
in triplicate and assessing the variant frequencies of
each independent test for samples of different viral loads
would be an important reliability test if adapting this
methodology to clinical samples. In addition, when the
Table 4 Association between the major drug resistance mutations emerging in treatment failures from the ALIVE















2v15 M41L RT 13.3%(5316) 6913 ZDV, 3TC H: 3TC, FTC
M184V RT 99.9%(7721) 51926 L: ABC, DDI
5v20 K103N RT 100%(5807) 513564 ZDV, 3TC, H: 3TC, FTC,
M184V RT 82.8%(5266) 425231 ABC, EFV EFV, NVP
L: ABC
PL: DDI
6v20 L90M PI 16.2%(3602) 179820 TDF, FTC, DRVr, RAL H: NFV
I: IDV, SQV
L: ATV, LPV, FPV,
9v33 M184V RT 99.8%(7493) 420158 ZDV, 3TC, ABC, RTV, FTC H: 3TC, FTC
L: ABC
PL: DDI
10v10 K103N RT 100%(5979) 40200 EFV, TDF, FTC H: 3TC, FTC, EFV, NVP
M184V RT 100%(5399) 40200 L: ABC
PL: DDI
16v11 E138K RT 7.6%(8955) 27149 3TC, RTV, LPV H: 3TC, FTC
M184V RT 56.6%(8222) 202190 I: RPV
S147G IN 7.0%(3123) 25006 L: ABC
PL: DDI, EFV, ETR, NVP
23v17 K103N RT 99.8%(6110) 16168 EFV, TDF, FTC H: 3TC, FTC, EFV, NVP
M184V RT 67.1%(6182) 10870 L: ABC
PL: DDI
27v05 M46I** PI 7.3%(3591) 1262 d4T, 3TC, ABC, IDVr L: NFV
PL: ATV, FPV, IDVr, LPV
(non-emerging DR related
to treatment: H: 3TC, L: ABC)
Boldface: correlation between mutation, treatment and drug resistance profile in each patient sample at the time point of treatment failure. H = high level drug
resistance, I = intermediate drug resistance, L = low level drug resistance, PL: potential low level drug resistance. Drug resistance mutations in italics are not
associated with any reported drug taken by the patients throughout the course of this study. *Coverage refers to the number of sequencing reads representing a
given nucleotide. **Patient 27 virus also harbored I54V, L90M, K103N and M184V at both time points. These mutations did not emerge between treatment
success and failure, but likely contributed to overall failure.
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exceeds the number of virus genome templates (due
to low viral loads) used to initiate the RT-PCR, then
the sequences are representing each template more
than once. This could result in false variant frequencies if
there is a bias for one template over another during the
PCR amplification. One way to address this concern
would be to require higher viral loads or multiplex more
samples on the sequencer to reduce the number of
sequencing reads to below the number of templates added
to the initial RT-PCR reaction. In this study, therefore, it
is possible that some of the frequencies presented for
samples with lower viral loads are not entirely accurate
due to possible template resampling (Additional file 3). It
remains questionable exactly what it means to have a
mutation present at 10%, 50% or 99%. With our currentunderstanding of drug resistance mutations, a mutation
present at any frequency could quickly turn into a
mutation present in nearly all viruses given drug selection
pressure. Therefore, an important drug resistance mutation
present at any frequency above the error rate would likely
warrant recommendations for changes to drug regimens
regardless of the actual frequency detected.
Lastly, one of the advantages of this MiSeq genotyping
method includes detection of integrase inhibitor drug
resistance mutations. One patient in the ALIVE cohort
(patient 16) with no prior exposure to integrase inhibitors
had a virus with a minority (7.6%) drug resistance mutation
to Elvitegravir (Tables 3 and 4). Such a mutation should be
considered when assigning a treatment regimen to this
individual already failing their current antiretroviral
regimen at the time of sample collection. The rollout of
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increases the need for integrase inhibitor drug resistance
testing prior to treatment initiation.
Comparison of Illumina MiSeq platform with other
platforms
We have already highlighted the advantages of the
Illumina MiSeq platform over our previous work
using the Roche/454 GS junior platform. Additionally,
Roche plans to phase out 454 machines in 2016 making
this platform obsolete for future development. This work
is also conceptually similar to recent work from Gibson
et al. describing comprehensive HIV drug resistance
genotyping across multiple HIV group M subtypes for
protease, reverse transcriptase and integrase inhibitors
as well as coreceptor tropism using the Ion Torrent
Personal Genome Machine [31]. There are, however,
specific advantages of our methodologies using the
MiSeq, including greater output (Illumina MiSeq: 13-15Gb
vs. Ion Torrent PGM: 1Gb) and reduced systemic sequen-
cing error rates (Illumina MiSeq: <0.4%, Ion Torrent: 1.78%)
[25]. Fewer errors reduce analysis time and improve data
reliability. In addition, our method is technically simpler,
requiring a single fragmented PCR amplicon over the three
required for the Gibson et al. method. Lastly, Illumina
MiSeq is the first and only next-generation sequencing
platform to receive FDA approval for assays developed on
that device, making it the optimal deep sequencing
platform to develop a HIV drug resistance assay for
possible clinical use in the future [39].
Data analysis considerations
Data analysis of next-generation sequencing techniques can
be exceptionally difficult and requires many considerations.
For example, when assessing viral variants related to HIV
drug resistance one must consider the viral load of the
samples to assess the possibility of template resampling
and its effects on frequency determination, error associated
with PCR amplification, systematic errors associated with
sequencing, and accurate data analysis.
One of the advantages of the described data analysis
approach is its relative simplicity using Geneious
software. This software is very user-friendly and does
not require a strong background in bioinformatics or
programming skills. The parameters used in this analysis
are fully defined in the Methods section and briefly
include 3 basic steps: (1) pair the paired-end sequences
together for each sample (2) trim ends based on quality
and reference map against an annotated HXB2 sequence
available here: (https://dholk.primate.wisc.edu/wiki/dho/
public/page.view?name=default) (3) call variants relative
to the HXB2 reference sequence. Steps 2 and 3 can
be performed simultaneously for all samples in a sequen-
cing run. Overall, only a few hours of hands-on time arenecessary to complete steps 1, initiate step 2 and initiate
step 3, with several hours of hands-off time to complete
steps 2 and 3. Once the variants have been detected, the
annotation table results can be exported out of Geneious
and assessed in Microsoft Excel or in a text editor to
determine which samples have which drug resistance
mutations and their frequencies. Depending on the
speed of the computer used to perform this analysis,
a run of 64 samples could be fully analyzed within
two days on a standard laptop with most of the analysis
performed in Geneious being hands-off. A fully automated
analysis approach would be required to use this method in
a clinical setting, however, the provided methods are
relatively quick and simple for research-based projects
and is considerably faster than Sanger-based data analysis
of 64 samples.
One of the sequence analysis challenges with working
with HIV drug resistance is that resistance is defined by
changes in amino acid sequence that could be rendered
by several different nucleotide variants. Many analysis
tools consider a single nucleotide variant at a time and
not necessarily the effect of two nucleotide changes from
a single sequence within a codon that might change an
amino acid. For example, a variant caller might call a
change from ATG (Met) to GTA (Val) as a mix of ATA
(Ile) and GTG (Val), considering each single nucleotide
change away from ATG as separate even though they
are present in the same sequence. We have worked with
the developers at Geneious to create a phased variant
detection approach that is accurate when assessing
nucleotide variants in the context of amino acid changes,
which is paramount to our analysis approach. This variant
detection approach is now built into the latest Geneious
software release.
Lastly, while we can identify drug resistance mutations
in the protease, reverse transcriptase and integrase regions
simultaneously with this assay, given the nature of library
formation and Illumina MiSeq sequencing we cannot ne-
cessarily associate together mutations found in one area of
the pol gene product with mutations found in another
area. With the paired-end technology it is possible to
link one mutation from the same template to a mutation
found ~600 bp downstream, but we cannot make those
associations with mutations that span further apart. In this
regard, this assay is not more informative than traditional
genotyping assays using Sanger-based sequencing, which
also cannot associate mutations together across multiple
pol gene products. The only way to reliably span the entire
pol gene from a single virus involves either cloning and
sequencing or limiting dilution PCR and sequencing. How-
ever, sequencing technologies continue to improve and as
error rates improve for techniques that sequence thousands
of nucleotides in a single sequencing read, linking together
all drug resistance mutations will become much easier.
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We have designed a universal primer set that amplifies
part of the pol gene from the major HIV-1 subtypes A,
B, C, D, CRF01_AE and CRF02_AG. These primers were
used in an Illumina MiSeq-based sequencing method for
the detection of drug resistance in primary HIV samples
from individuals failing treatment after release from prison.
We characterized drug resistance to protease, reverse
transcriptase and integrase inhibitors simultaneously.
54% of the patients failing treatment harbored mutations
in their virus at the time of treatment failure that were not
present before treatment. Of the patients with virus
harboring major drug resistance mutations, all but one
patient had virus with mutations associated with resist-
ance to the self-reported treatment regimen at the time of
treatment failure. This finding suggests that virologic
failure associated with incarceration may be due to
the development of drug resistance mutations in
about half of cases. This implies that actions to prevent
drug resistance, such as preventing treatment interruption
during and after incarceration, may reduce virologic failure
associated with incarceration. 59% of all the mutations
found were present at frequencies between 2% and 20% of
the within-host virus population and would likely have been
missed by traditional Sanger-based genotyping techniques.
The technique presented in this manuscript should facili-
tate larger studies to elucidate the role(s) of these minority
variants in treatment failure- an important consideration as
genotyping moves to more sensitive sequencing platforms.
Additionally, these methods can be adapted to sequence
any region of the HIV virus by designing new primer sets
to study a variety of questions related to HIV evolution.
The results shown here suggest that the presented method
is a significant advance over current HIV drug resistance
genotyping by improving sensitivity, broadening the
detection of mutations from protease through integrase,
and improving genotyping in non-B HIV subtypes.
Methods
Ethics statement
The subjects used in this study provided informed written
consent. The phlebotomy protocol and consent forms were
approved by the Internal Review Board of Johns Hopkins
University. The collected samples were de-identified and
sent to the University of Wisconsin-Madison for sequen-
cing. The protocol was approved by the Health Sciences
Institutional Review Board at the University of Wisconsin-
Madison (protocol number 2012–0140).
Study subjects
Sixty-two participant samples were selected for inclusion
in this study. These samples originated from individuals
with a history of injection drug use who participated in the
ALIVE study between 1997 and 2009 [29,40-42]. Selectedparticipants were successfully treated with antiretroviral
therapy (ART) prior to incarceration, but failed ART after
release from prison. A baseline, pre-incarceration blood
sample collected at a study visit before viral suppression
was achieved and a follow-up sample collected after release
from prison and treatment failure were obtained for this
study (Additional file 3). As outlined in Additional file 3,
many study participants were not drug naïve at the first
time point we genotyped, but either failed their drug
regimen or stopped taking antiretroviral drugs leading
to an increase in viral load at the time point we sampled.
Either a change in regimen or restarting a drug regimen
resulted in viral suppression at the time point following
the first time point we sampled. However, at a subsequent
time point that coincided with the release from
prison, individuals failed treatment again, which is the
second time point that we tested. The range of viral
load of these samples was 799–1,110,000 copies/ml.
Treatment regimens were self-reported by the patients
at each time point a sample was collected.
HIV viral stocks
Viral stocks containing subtypes A, B, C, D, CRF01_AE,
and CRF02_AG were obtained from the NIH AIDS
Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH (cat. #11412) and used to test the
subtype specificity of our primers. Viruses were provided
by Robert Gallo, Smita Kularni, UNAIDS, Nelson Michael,
and Victoria Polonis. The pHXBn-PLAP-IRES-N+ plasmid
(cat. #3610) was obtained through the NIH AIDS research
and reference reagent program, Division of AIDS, NIAID,
NIH from Dr. Benjamin K. Chen and Dr. David Baltimore.
To produce a clonal viral stock to assess error associated
with our method, the pHXBnPLAP-IRES-N+ (HXBn)
plasmid was transfected into 239 T packaging cells using
the Xfect Transfection Reagent (Clontech). The super-
natant was collected two days after transfection to limit
virus production to a single round and the virus was
quantitated using the Lenti-X qRT-PCR titration kit
(Clontech). Viral RNA was isolated from this supernatant
(viral load = 115,000 copies/ml) and subjected to one-step
RT-PCR and sequenced using the same protocol that was
used to sequence patient samples. The initial plasmid
DNA was also sequenced using the same protocol as the
research samples without the initial reverse transcription
step. Both DNA and viral RNA starting templates are
expected to have no variants relative to the HXB2
reference sequence (GenBank NC_001802). In addition,
we sequenced the protease and reverse transcriptase gene
products from the HIV plasmid used to generate the
clonal virus using a Sanger-based approach as a standard
to verify the pol gene sequence in the plasmid. This verifi-
cation revealed two mutations in (HXB2 positions 1805
and 2473) the plasmid that were not expected based on
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These mutations in the plasmid were found in 99% of the
viral RNA sequenced from the clonal virus stock and were
ignored during analysis as changes in the plasmid relative
to the published HXB2 sequence. All other variants found
by Illumina sequencing in either the plasmid or the viral
stock were considered “false” variants that likely resulted
from error in the PCR, sequencing, or analysis of the
sequences. We used the maximum frequency found
as “false” variants (0.9%) as the minimum frequency
threshold for “real” variants found within a patient’s
viral population (1.0%) that do not likely stem from
error associated with the sequencing method.
Primer design
Sequences representing multiple HIV subtypes were
downloaded from the Los Alamos National Laboratory
HIV database and aligned using the software program
Geneious version 5.6. Regions of the pol gene flanking all
known drug resistance mutations found in the protease,
reverse transcriptase, and integrase protein coding regions
were searched for conservation between group M HIV
isolates. Two regions containing high conservation were
identified and used to design PCR primers. Primers were
optimized for melting temperatures, GC content and
reduced hairpin and/or primer dimer formation as
much as possible given restraints of the conserved regions
(NetPrimer, Premier Biosoft International). The sequences
of these primers named HIV2252-F and HIV5073-R can
be found in Additional file 5 (nested primers). The
forward primer contains a mismatch in the middle of
the primer for some subtypes and is therefore designed
with a degenerate nucleotide at that position (R = A/G).
The reverse primer contained a mismatch in the middle
of the sequence in some subtype C isolates. Two separate
reverse primers were designed and tested with subtype C
isolates. The primer that matched all group M isolates but
contained a mismatch with some subtype C isolates
amplified all subtypes well including all subtype C viruses
tested and was used in this study (HIV5073-R). The
expected PCR product size is 2892 bp. The external primers,
as shown in Additional file 5, were previously designed
(Todd Allen, personal communication).
Sample preparation and PCR amplification
A schematic diagram representing the major steps to pre-
pare samples for drug resistance genotyping using the
method described in this paper is presented in Figure 1.
Plasma from each sample was centrifuged at 14,000 x rpm
at 4°C for 1 hour to concentrate virus for viral RNA
extraction using the QIAamp Viral RNA Mini Kit
(Qiagen). Viral RNA was subjected to one-step RT-PCR
amplification using Superscript III Reverse Transcriptase
and High Fidelity Platinum Taq Polymerase (Invitrogen)and the primers HIV2252-F and HIV5073-R. RT-PCR
conditions were as follows: reverse transcription was
performed at 50°C for 30 min., the enzyme was denatured
at 94°C for 2 min., 40 cycles of amplification was
performed at 94°C for 15 sec., 55°C for 30 sec., and 68°C
for 3 min., followed by a 68°C extension for 10 minutes.
Amplification was more reliable with the addition of 5%
DMSO to the PCR reaction. Products were visualized on a
DNA Flashgel (Lonza) and any sample containing
PCR amplicons other than the product of interest was
electrophoresed on a 1% agarose gel and the expected
2.8 kb amplicon was extracted using a Qiagen gel
extraction MinElute kit (Qiagen). All samples were
further purified using size exclusion beads (Agilent XP)
to remove primer dimers at a 1:1 DNA:bead (volume)
ratio. Samples that failed to amplify with a single
round of PCR were subjected to nested PCR using
the following primers in an external PCR (Additional file 5):
HIV737-F and HIV5578-R. External PCR conditions
included reverse transcription at 50°C for 60 min.,
polymerase activation at 94°C for 2 min., 2 cycles of 94°C
for 15 sec., 60°C for 30 sec., and 68°C for 4 min. and
45 sec., 2 cycles of 94°C for 15 sec., 58°C for 30 sec., and
68°C for 4 min. and 45 sec., 31 cycles of 94°C for 15 sec.,
55°C for 30 sec., and 68°C for 4 min. and 45 sec. followed
by a 10 min. extension at 68°C. 5 μl of the 25 μl external
PCR was used in a nested PCR using the conditions
for single round PCR described above excluding the
reverse transcription step. The nested primer set is
shown in Additional file 5 and is the same primer set
used for samples requiring only a single round of
amplification.
Amplicon fragmentation and sequencing
Following size exclusion purification, PCR amplicons
were quantitated using picogreen dye and the Qubit
(Invitrogen) fluorometer or DTX 800 Multimode detector
plate reader (Beckman Coulter). 1 ng of each sample was
fragmented using Nextera XT transposon technology
(Epicentre). The average size of the fragmented PCR
amplicons was 774 bp (range 519-1060 bp) as detected by
bioanalysis (Agilent). Following Nextera tagmentation,
Illumina sequencing adaptors and molecular tags were
added via PCR, size exclusion bead purification was
performed, and samples were quantitated using picogreen
as previously described. Individual samples were then
pooled at equimolar ratios (1–2 nM/sample, depending
on run) based on the mean size of each library. The
final diluted 8–9 pM pool was denatured using sodium
hydroxide according to the Illumina MiSeq protocol
and 1% denatured PhiX beads were added as a sequencing
control. Samples were loaded into a 300-cycle MiSeq
cartridge and sequenced This protocol is also amenable to
the updated Illumina 500 and 600 cycle MiSeq kits.
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Data was analyzed using Geneious version 5.6 software.
A HXB2 reference sequence (GenBank accession #
NC_001802) was uploaded into Geneious and all drug
resistance mutations were manually annotated onto the
sequence to generate an annotated reference sequence for
reference-based assembly (https://dholk.primate.wisc.edu/
wiki/dho/public/page.view?name=default). Sequences are
demultiplexed automatically on the MiSeq as part of the
data processing steps and two paired .fastq files are gener-
ated for each sample representing the two paired-end
reads. After importing the .fastq files from the MiSeq into
Geneious, the two sequence lists from each sample were
paired. Next, all sequences were trimmed at the ends as
part of the assembly process using the modified-Mott
algorithm and quality scores assigned by the sequencing
base caller. This algorithm trims the ends to the point
where trimming no longer improves the error rate by
more than the error probability limit threshold set, in this
case 0.001, or a 0.1% error rate. Sequences were then
mapped to the annotated reference sequence with the fol-
lowing parameters: Gaps were allowed with a maximum of
15% per read and gap size of 15, word length was set to 14,
maximum mismatches per read were set to 25%, minimum
overlap identity was set to 80%, maximum ambiguity was
set to 16 and “search more thoroughly for poor matching
reads” was selected. In general, the reference assembler uses
a seed and expand-type mapper, followed by a fine-tuning
step that was set to none (fast / read mapping) for this ana-
lysis. All nucleotide variants represented by at least 5
sequencing reads and at a frequency >1% from the refer-
ence sequence were then called using the variant finder.
This threshold was set based on previous work to establish
minimum sequencing read coverage for next-generation
sequencing [22,30]. To ensure that variants were called
relative to the correct codon, the “merge adjacent varia-
tions” and “use separate annotations for each variant at a
position” were selected. Geneious developed a variant finder
analysis tool that allows amino acid variants within a codon
to be called together when present on the same sequence to
accurately reflect the effects of all single nucleotide changes
on the amino acid sequence. This variant finder was used
as a plugin with Geneious 5.6 at the time of this analysis
but has since been incorporated into Geneious starting with
version 6.1 and is now part of their standard Geneious Pro
software. Variants and their frequencies were exported into
an excel document and filtered for those present in amino
acid sites known to correlate with drug resistance based on
the Stanford drug resistance database list and the 2012 list
of IAS-USA HIV drug resistance mutations as annotated
on the reference sequence. Frequency of each variant and
the number of sequences representing each nucleotide
position containing a variant away from the reference
sequence was also calculated by the variant finder plugin.Phylogenetic analysis
A consensus sequence was constructed from the reference-
based assemblies performed on each sample using the 50%
strict setting. These nucleotide sequences were aligned by
the CLUSTAL algorithm in MEGA 6 [43]. A maximum
likelihood (ML) phylogenetic analysis was conducted
based on the GTR + G + I model, which was chosen
using the Bayes Information Criterion in MEGA 6. The
reliability of the clustering patterns in ML trees was
tested by bootstrapping; 1000 bootstrap pseudo-samples
were used.Additional files
Additional file 1: 1.0% agarose gel image of RT-PCR products
amplified with universal primers from 19 NIH HIV isolates.
Additional file 2: All non-synonymous variants detected while
sequencing HXB2 clonal stock viruses from three independent PCR
amplifications and two independent sequencing reactions to determine
the error rates associated with this sequencing method.
Additional file 3: Patient information from samples collected in the
ALIVE cohort.
Additional file 4: Maximum likelihood phylogenetic analysis of the
assembled sequences from the ALIVE cohort with reference sequences
representing subtypes A, B, C, D, CRF01_AE and CRF02_AG using the
Bayes Information Criterion in MEGA6.
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